ArticleMalaria journal2019
Reducing malaria burden and accelerating elimination with long-lasting systemic insecticides: a modelling study of three potential use cases.
Article in Malaria journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Modelling the impact of adopting new-generation insecticide-treated nets on malaria transmission and insecticide resistance.Parasites & vectors · 2026Article
- Selection of the optimal long-acting injectable formulation of ivermectin for use in humans to target malaria vectors in Western Africa: evaluation of pharmacokinetics and mosquitocidal efficacy in cattle under laboratory conditions.Parasites & vectors · 2026Article
- Modelling the impact of ivermectin-based optimal strategies on malaria control: the role of formulation, coverage, and mosquitocidal efficacy timing.EBioMedicine · 2026Article
- Agent-based simulation of seasonal malaria chemoprevention strategy in Southern Tanzania: comparing dihydroartemisinin-piperaquine with or without primaquine.Malaria journal · 2026Article
- High resolution physically based modelling reveals malaria incidence reduction by vector control measures.Scientific reports · 2026Article
- Effect of malaria chemoprevention for school-age children across transmission archetypes: a modelling study.The Lancet. Global health · 2025Article
- The mosquitocidal activity of isoxazoline derivatives afoxolaner, lotilaner, and fluralaner are not affected by mosquito sugar or antibiotic treatment.Scientific reports · 2025Article
- Design and selection of drug properties to increase the public health impact of next-generation seasonal malaria chemoprevention: a modelling study.The Lancet. Global health · 2024Article
- A field bioassay for assessing ivermectin bio-efficacy in wild malaria vectors.Malaria journal · 2023Article
- Population replacement gene drive characteristics for malaria elimination in a range of seasonal transmission settings: a modelling study.Malaria journal · 2022Article
- Leveraging mathematical models of disease dynamics and machine learning to improve development of novel malaria interventions.Infectious diseases of poverty · 2022Article
- Vector genetics, insecticide resistance and gene drives: An agent-based modeling approach to evaluate malaria transmission and elimination.PLoS computational biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile bed nets and insecticide spraying have had significant impact on malaria burden in many endemic regions, outdoor vector feeding and insecticide resistance may ultimately limit their contribution to elimination and control campaigns. Complementary vector control methods such as endectocides or systemic insecticides, where humans or animals are treated with drugs that kill mosquitoes upon ingestion via blood meal, are therefore generating much interest. This work explores the conditions under which long-lasting systemic insecticides would have a substantial impact on transmission and burden.
methodsHypothetical long-lasting systemic insecticides with effective durations ranging from 14 to 90 days are simulated using an individual-based mathematical model of malaria transmission. The impact of systemic insecticides when used to complement existing vector control and drug campaigns is evaluated in three settings-a highly seasonal high-transmission setting, a near-elimination setting with seasonal travel to a high-risk area, and a near-elimination setting in southern Africa.
resultsAt 60% coverage, a single round of long-lasting systemic insecticide with effective duration of at least 60 days, distributed at the start of the season alongside a seasonal malaria chemoprevention campaign in a high-transmission setting, results in further burden reduction of 30-90% depending on the sub-populations targeted. In a near-elimination setting where transmission is sustained by seasonal travel to a high-risk area, targeting high-risk travellers with systemic insecticide with effective duration of at least 30 days can result in likely elimination even if intervention coverage is as low as 50%. In near-elimination settings with robust vector control, the addition of a 14-day systemic insecticide alongside an anti-malarial in mass drug administration (MDA) campaigns can decrease the necessary MDA coverage from about 85% to the more easily achievable 65%.
conclusionsWhile further research into the safety profile of systemic insecticides is necessary before deployment, models predict that long-lasting systemic insecticides can play a critical role in reducing burden or eliminating malaria in a range of contexts with different target populations, existing malaria control methods, and transmission intensities. Continued investment in lengthening the duration of systemic insecticides and improving their safety profile is needed for this intervention to achieve its fullest potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.